Analysts Set Vor Biopharma Inc. (NYSE:VOR) Price Target at $6.07

Key Points

• Vor Biopharma Inc. (NYSE:VOR) has received a consensus rating of "Moderate Buy" from nine brokerages, with four hold ratings and five buy ratings reported.
• Major shareholder Reprogrammed Interchange LLC sold over 806,000 shares of Vor Biopharma's stock, decreasing their ownership by 2.14% and raising concerns among investors.
• Vor Biopharma's stock is currently trading at $1.52, with a market capitalization of approximately $192.56 million, and it has experienced a 1-year high of $3.29 and a low of $0.13.

Vor Biopharma Inc. (NYSE:VOR - Get Free Report) has earned a consensus rating of "Moderate Buy" from the nine brokerages that are presently covering the stock, Marketbeat Ratings reports. Four research analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $121.3333.

Several equities research analysts have commented on VOR shares. HC Wainwright reaffirmed a "buy" rating and issued a $60.00 target price on shares of Vor Biopharma in a research note on Thursday, August 14th. Wedbush reissued an "outperform" rating on shares of Vor Biopharma in a report on Thursday, June 26th.

Vor Biopharma Price Performance

Shares of VOR stock traded down $3.16 on Thursday, hitting $27.24. The company's stock had a trading volume of 654,392 shares, compared to its average volume of 380,475. The firm's fifty day moving average price is $40.37 and its 200-day moving average price is $22.93. Vor Biopharma has a fifty-two week low of $2.62 and a fifty-two week high of $65.80. The stock has a market capitalization of $3.45 billion, a price-to-earnings ratio of -16.51 and a beta of 2.05.

Insider Activity

In other Vor Biopharma news, major shareholder Reprogrammed Interchange Llc sold 447,278 shares of the firm's stock in a transaction on Tuesday, September 16th. The shares were sold at an average price of $1.54, for a total value of $688,808.12. Following the transaction, the insider directly owned 32,781,209 shares of the company's stock, valued at approximately $50,483,061.86. This trade represents a 1.35% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last 90 days, insiders have sold 756,918 shares of company stock worth $12,573,293. 0.45% of the stock is owned by insiders.

Institutional Trading of Vor Biopharma

A number of hedge funds and other institutional investors have recently bought and sold shares of VOR. Money Concepts Capital Corp raised its stake in shares of Vor Biopharma by 106.1% during the first quarter. Money Concepts Capital Corp now owns 51,535 shares of the company's stock worth $37,000 after acquiring an additional 26,535 shares in the last quarter. Goldman Sachs Group Inc. boosted its stake in Vor Biopharma by 218.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company's stock worth $61,000 after purchasing an additional 58,247 shares in the last quarter. XTX Topco Ltd bought a new position in Vor Biopharma in the 2nd quarter worth about $66,000. OMERS ADMINISTRATION Corp bought a new position in Vor Biopharma in the 1st quarter worth about $100,000. Finally, Jane Street Group LLC bought a new position in Vor Biopharma in the 1st quarter worth about $140,000. Institutional investors own 97.29% of the company's stock.

About Vor Biopharma

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.